[HTML][HTML] Exploring immunotherapy in colorectal cancer
J Weng, S Li, Z Zhu, Q Liu, R Zhang, Y Yang… - Journal of hematology & …, 2022 - Springer
Chemotherapy combined with or without targeted therapy is the fundamental treatment for
metastatic colorectal cancer (mCRC). Due to the adverse effects of chemotherapeutic drugs …
metastatic colorectal cancer (mCRC). Due to the adverse effects of chemotherapeutic drugs …
[HTML][HTML] Cancer vaccines: Building a bridge over troubled waters
MLC Sellars, CJ Wu, EF Fritsch - Cell, 2022 - cell.com
Cancer vaccines aim to direct the immune system to eradicate cancer cells. Here we review
the essential immunologic concepts underpinning natural immunity and highlight the …
the essential immunologic concepts underpinning natural immunity and highlight the …
[HTML][HTML] The challenges of tumor mutational burden as an immunotherapy biomarker
DL Jardim, A Goodman, D de Melo Gagliato… - Cancer cell, 2021 - cell.com
Tumor mutational burden (TMB) reflects cancer mutation quantity. Mutations are processed
to neo-antigens and presented by major histocompatibility complex (MHC) proteins to T …
to neo-antigens and presented by major histocompatibility complex (MHC) proteins to T …
[HTML][HTML] CDK inhibitors in cancer therapy, an overview of recent development
M Zhang, L Zhang, R Hei, X Li, H Cai… - American journal of …, 2021 - ncbi.nlm.nih.gov
Dysregulated cell division, which leads to aberrant cell proliferation, is one of the key
hallmarks of cancer. Therefore, therapeutic targets that block cell division would be effective …
hallmarks of cancer. Therefore, therapeutic targets that block cell division would be effective …
Targeting the DNA damage response in immuno-oncology: developments and opportunities
Immunotherapy has revolutionized cancer treatment and substantially improved patient
outcome with regard to multiple tumour types. However, most patients still do not benefit …
outcome with regard to multiple tumour types. However, most patients still do not benefit …
[HTML][HTML] A proteogenomic portrait of lung squamous cell carcinoma
Lung squamous cell carcinoma (LSCC) remains a leading cause of cancer death with few
therapeutic options. We characterized the proteogenomic landscape of LSCC, providing a …
therapeutic options. We characterized the proteogenomic landscape of LSCC, providing a …
Targeting the epigenetic regulation of antitumour immunity
Dysregulation of the epigenome drives aberrant transcriptional programmes that promote
cancer onset and progression. Although defective gene regulation often affects oncogenic …
cancer onset and progression. Although defective gene regulation often affects oncogenic …
Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer
Circulating tumour DNA (ctDNA) in blood plasma is an emerging tool for clinical cancer
genotyping and longitudinal disease monitoring. However, owing to past emphasis on …
genotyping and longitudinal disease monitoring. However, owing to past emphasis on …
CD8+ T cells regulate tumour ferroptosis during cancer immunotherapy
Cancer immunotherapy restores or enhances the effector function of CD8+ T cells in the
tumour microenvironment,. CD8+ T cells activated by cancer immunotherapy clear tumours …
tumour microenvironment,. CD8+ T cells activated by cancer immunotherapy clear tumours …
[HTML][HTML] Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised …
Background Metastatic castration-resistant prostate cancer is enriched in DNA damage
response (DDR) gene aberrations. The TOPARP-B trial aims to prospectively validate the …
response (DDR) gene aberrations. The TOPARP-B trial aims to prospectively validate the …